JP Morgan Chase’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-441
| Closed | -$364 | – | 7395 |
|
|
2025
Q1 | $364 | Sell |
441
-7
| -2% | -$7 | ﹤0.01% | 6732 |
|
|
2024
Q4 | $426 | Sell |
448
-4
| -0.9% | -$4 | ﹤0.01% | 6818 |
|
|
2024
Q3 | $452 | Buy |
452
+102
| +29% | +$113 | ﹤0.01% | 6811 |
|
|
2024
Q2 | $434 | Hold |
350
| – | – | ﹤0.01% | 6701 |
|
|
2024
Q1 | $455 | Hold |
350
| – | – | ﹤0.01% | 6733 |
|
|
2023
Q4 | $438 | Sell |
350
-1,171
| -77% | -$1.3K | ﹤0.01% | 6942 |
|
|
2023
Q3 | $1.98K | Sell |
1,521
-66,447
| -98% | -$107K | ﹤0.01% | 6544 |
|
|
2023
Q2 | $117K | Sell |
67,968
-2,674,233
| -98% | -$4.25M | ﹤0.01% | 5395 |
|
|
2023
Q1 | $4M | Buy |
2,742,201
+172,609
| +7% | +$331K | ﹤0.01% | 2998 |
|
|
2022
Q4 | $4.16M | Buy |
2,569,592
+16,000
| +0.6% | +$36.8K | ﹤0.01% | 2980 |
|
|
2022
Q3 | $8.55M | Sell |
2,553,592
-61,926
| -2% | -$280K | ﹤0.01% | 2285 |
|
|
2022
Q2 | $9.52M | Buy |
2,615,518
+50,471
| +2% | +$229K | ﹤0.01% | 2208 |
|
|
2022
Q1 | $18.5M | Buy |
2,565,047
+1,123,528
| +78% | +$9.58M | ﹤0.01% | 1828 |
|
|
2021
Q4 | $19.6M | Sell |
1,441,519
-46,170
| -3% | -$722K | ﹤0.01% | 1840 |
|
|
2021
Q3 | $31.2M | Sell |
1,487,689
-71,499
| -5% | -$1.54M | ﹤0.01% | 1453 |
|
|
2021
Q2 | $37.3M | Sell |
1,559,188
-63,850
| -4% | -$1.62M | ﹤0.01% | 1372 |
|
|
2021
Q1 | $47.5M | Buy |
1,623,038
+18,277
| +1% | +$535K | 0.01% | 1187 |
|
|
2020
Q4 | $47.9M | Buy |
+1,604,761
| New | +$50.3M | 0.01% | 1094 |
|
JP Morgan Chase's KRON Position: Q2 2025 in Review
JP Morgan Chase sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 441 shares — an estimated $364 sold.
JP Morgan Chase first reported a position in KRON in Q4 2020 and held it in 18 quarters. The position peaked at $47.9M in Q4 2020. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- JP Morgan Chase reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- JP Morgan Chase sold 441 Kronos Bio shares in Q2 2025, an estimated $364.
- JP Morgan Chase first reported a position in Kronos Bio in Q4 2020 and held it in 18 quarters.
- JP Morgan Chase's Kronos Bio position peaked at $47.9M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.